TABLE 2.
DMT Dosing and Acquisition Cost
| DMT | Dose, Frequency, Route | Doses per Pack | Packs per Year | Wholesale Acquisition Price per Package (2015 U.S. $) | Wholesale Acquisition Price per Year (2015 U.S. $) |
|---|---|---|---|---|---|
| Model 1: PEG | |||||
| PEG24 | 125 μg Every 14 days Subcutaneous |
2 | 13 | 5,034.00 | 65,442.00 |
| IM IFN beta-1a25 | 30 μg Once a week Intramuscular |
4 | 13 | 5,034.00 | 5,034.00 |
| SC IFN beta-1b26 | 0.25 mg Every other day Subcutaneous |
15 | 12.2 | 3,740.75 | 45,637.00 |
| GA27 | 20 mg/mL Every day Subcutaneous |
30 | 12.2 | 6,110.50 | 6,110.50 |
| FIN28 | 0.5 mg Every day Oral |
30 | 12.2 | 5,831.22 | 5,831.22 |
| NAT29 | 300 mg Every 4 weeks Intravenous infusion |
1 | 13 | 4,960.00 | 64,480.00 |
| DMF30 | SD: 120 mg Twice daily for 7 days MD: 240 mg Twice daily after 7 days Oral |
SD: 14 MD: 60 |
12.9 | SD: 1,274.00 MD: 5,460.00 |
66,248.00 |
| Model 2: ALT | |||||
| ALT31 | Year 1:12 mg/day 5 consecutive days Year 2:12 mg/day 3 consecutive days Intravenous infusion |
1 | Year 1: 5 Year 2: 3 |
19,750.00 | Year 1: 98,750.00 Year 2: 59,250.00 |
| IFN beta-1a 44 μg32 | 44 μg 3 times per week Subcutaneous |
12 | 13 | 5,433.70 | 70,638.00 |
ALT = alemtuzumab; DMF = dimethyl fumarate; DMT = disease-modifying therapy; FIN = fingolimod; GA = glatiramer acetate; IFN = interferon; IM = intramuscular; MD = maintenance dose; NAT = natalizumab; PEG = peginterferon beta-1a; SC = subcutaneous; SD = starting dose.